PfizerPFE
Daily Market Briefing
Latest briefing
Pfizer's stock remains stable at $26.87 amid market fluctuations.
Over the past 24 hours, Pfizer's stock price has shown minimal movement, closing at $26.87 on August 17, 2026. This stability reflects a lack of significant market-moving news during this period.
Previous briefings
Pfizer's stock price remains steady at $26.79 amid market stability.
Over the past 24 hours, there have been no significant developments affecting Pfizer's stock performance. The stock closed at $26.79 on Friday, August 14, 2026, with minimal intraday fluctuations. Investors are awaiting upcoming events, including the third-quarter 2026 dividend payment scheduled for September 1, 2026.
No significant market-moving news for Pfizer (PFE) in the past 24 hours.
Over the past 24 hours, there have been no significant developments affecting Pfizer's stock performance. The company continues to focus on its strategic initiatives, including cost-saving measures and expanding its oncology and obesity portfolios. Traders should monitor upcoming earnings reports and industry trends for potential impacts on Pfizer's stock.
Pfizer's Q3 2026 dividend of $0.43 per share declared, payable September 1.
Pfizer's Board of Directors declared a quarterly cash dividend of $0.43 per share for Q3 2026, payable on September 1, 2026, to shareholders of record as of July 24, 2026. This marks the 351st consecutive quarterly dividend paid by the company. No significant market-moving news has been reported in the past 24 hours.
Pfizer's stock rises 1.84% to $26.80 amid steady dividend payouts.
In the past 24 hours, Pfizer's stock price increased by 1.84%, closing at $26.80. This uptick aligns with the company's consistent dividend strategy, with the most recent quarterly dividend of $0.43 per share declared in April 2026.
Pfizer's stock drops 1.18% to $26.31 amid market fluctuations
Pfizer's stock experienced a slight decline of 1.18%, closing at $26.31 on August 12, 2026. This movement reflects broader market trends rather than company-specific news.
Pfizer's Q1 2026 Dividend Declared at $0.43 per Share
Pfizer's Board of Directors has declared a quarterly cash dividend of $0.43 per share for Q1 2026, payable on March 6, 2026, to shareholders of record as of January 23, 2026. This marks the 349th consecutive quarterly dividend paid by the company.
No significant market-moving news for Pfizer (PFE) in the past 24 hours.
Over the past 24 hours, there have been no significant developments affecting Pfizer's stock performance. The company continues to focus on its strategic initiatives, including cost realignment and expansion into oncology and obesity treatments. Investors are advised to monitor upcoming earnings reports and industry trends for potential impacts on Pfizer's performance.
Pfizer's stock remains steady at $26.76 amid recent developments
Over the past 24 hours, there have been no significant market-moving news regarding Pfizer. The stock closed at $26.76 on August 7, 2026, with a slight increase of $0.55 (2.09%) from the previous close. The intraday high was $26.75, and the low was $26.05. The market capitalization stands at $152.5 billion, with a P/E ratio of 35.21 and an EPS of $0.76.
Pfizer's stock price remains steady at $26.76 amid market stability.
Over the past 24 hours, there have been no significant developments affecting Pfizer's stock performance. The stock closed at $26.76 on August 7, 2026, reflecting market stability. Investors are awaiting upcoming earnings reports and potential regulatory updates for future guidance.
Pfizer's stock (PFE) closes at $26.76, up 2.09% on August 7, 2026.
In the past 24 hours, there have been no significant developments affecting Pfizer's stock performance. The stock closed at $26.76 on August 7, 2026, reflecting a 2.09% increase from the previous close. No major news or events have been reported that would influence the stock's movement.
Pfizer's stock (PFE) closes at $26.20, up 1.51% on August 6, 2026.
In the past 24 hours, there have been no significant developments affecting Pfizer's stock performance. The stock closed at $26.20 on August 6, 2026, marking a 1.51% increase from the previous close. No major news or events have been reported that would influence the stock's movement.
Pfizer's stock price rises 1.5% to $25.81 amid steady market performance
Over the past 24 hours, Pfizer's stock (PFE) has experienced a modest increase of 1.5%, closing at $25.81. This uptick reflects stable market conditions without significant news impacting the company's performance.
Pfizer's stock price rises 1.48% to $25.41 amid steady performance.
In the past 24 hours, Pfizer's stock (PFE) experienced a modest increase of 1.48%, closing at $25.41. This uptick reflects the company's stable market performance, with no significant news or events impacting its stock price during this period.
No significant market-moving news for Pfizer (PFE) in the past 24 hours.
Over the past 24 hours, there have been no significant developments affecting Pfizer's stock performance. The company continues to focus on its strategic initiatives, including cost-saving measures and expanding its oncology and obesity treatment portfolios. Investors are advised to monitor upcoming earnings reports and industry trends for potential impacts on Pfizer's performance.
No significant market-moving news for Pfizer (PFE) in the past 24 hours.
Over the past 24 hours, there have been no significant developments affecting Pfizer's stock performance. The company continues to focus on its strategic initiatives, including cost-saving measures and expansion into oncology and obesity treatments. Investors are advised to monitor upcoming earnings reports and industry trends for potential impacts on Pfizer's performance.
Pfizer's Q2 2026 dividend of $0.43 per share declared, payable June 12, 2026.
Pfizer's Board of Directors declared a quarterly cash dividend of $0.43 per share for Q2 2026, payable on June 12, 2026, to shareholders of record as of May 8, 2026. This marks the 350th consecutive quarterly dividend paid by the company.
Pfizer's stock price remains steady at $25.01 amid market stability.
Over the past 24 hours, there have been no significant developments affecting Pfizer's stock performance. The stock closed at $25.01 on July 31, 2026, with minimal intraday fluctuations. Investors are awaiting upcoming earnings reports and potential regulatory updates for future guidance.
Pfizer's Q2 2026 Dividend Declared at $0.43 per Share
Pfizer's Board of Directors has declared a quarterly cash dividend of $0.43 per share for the second quarter of 2026, payable on June 13, 2025, to shareholders of record as of May 9, 2025. This marks the 346th consecutive quarterly dividend paid by the company.
No significant market-moving news for Pfizer (PFE) in the past 24 hours.
Over the past 24 hours, there have been no significant developments affecting Pfizer's stock performance. The company continues to focus on its strategic initiatives, including cost-saving programs and acquisitions in oncology and obesity treatments. Investors are advised to monitor upcoming earnings reports and industry trends for potential impacts on Pfizer's stock.
Pfizer's stock rises 2.43% to $25.25 amid positive analyst outlook.
Pfizer's stock price increased by 2.43% to $25.25, following positive analyst assessments. RBC Capital upgraded Pfizer's rating to 'Sector Perform' with a $25.00 price target, citing improved valuation and upcoming catalysts. Additionally, the Swiss National Bank increased its stake in Pfizer by 7.1%, now holding approximately 16.7 million shares valued at $468.5 million.
Pfizer's stock remains stable at $24.67 amid Gabelli Funds' reduced stake.
In the past 24 hours, there have been no significant developments affecting Pfizer's stock performance. The stock closed at $24.67 on July 27, 2026, with an intraday high of $24.875 and a low of $24.45. Gabelli Funds LLC recently reduced its position in Pfizer by 11.8%, selling 67,900 shares and retaining 508,600 shares valued at approximately $14.3 million.
Pfizer's stock drops 1.9% to $24.53 amid cautious analyst outlook
Pfizer's stock declined by 1.9% to $24.53, influenced by cautious analyst perspectives and recent company developments.
Pfizer's stock remains stable amid strategic shift and AI healthcare focus.
Pfizer is navigating a post-pandemic landscape by refocusing on its core pharmaceutical portfolio, including oncology, vaccines, and internal medicine. The company is also exploring opportunities in AI healthcare to enhance diagnostics and treatment decisions. Despite these strategic shifts, there have been no significant market-moving developments in the past 24 hours.
Pfizer's stock drops 1.88% to $24.54 amid unusual options trading volume.
In the past 24 hours, Pfizer's stock declined by 1.88% to $24.54, accompanied by unusually high options trading volume. This suggests increased investor activity, potentially indicating market uncertainty or speculative interest.
Pfizer's stock remains stable at $25.01 amid recent developments.
In the past 24 hours, Pfizer's stock price has remained relatively unchanged at $25.01. Recent developments include a significant increase in call option activity and a notable sale of shares by PNC Financial Services Group Inc. However, no major news has emerged to significantly impact the stock's performance.
Pfizer's stock declines 0.42% amid new patent lawsuits over COVID-19 vaccine technology.
Pfizer's stock experienced a slight decline of 0.42% following the announcement of new international patent lawsuits filed by Arbutus Biopharma and Genevant Sciences. These lawsuits target Pfizer/BioNTech's use of mRNA lipid nanoparticle technology in their COVID-19 vaccine, seeking injunctions and monetary damages across Canada and much of the European Union. This legal action extends existing U.S. patent disputes into multiple major markets, potentially impacting Pfizer's mRNA franchise.
Pfizer's stock remains steady at $24.94 amid mixed market signals.
Over the past 24 hours, Pfizer's stock price has remained relatively unchanged, closing at $24.94 on July 21, 2026. This stability comes despite recent developments, including a 1.3% increase in share price on July 16, 2026, following FDA approval for a new bladder cancer regimen. However, the stock has also faced challenges, such as a 2.7% decline on June 24, 2026, due to a Phase 3 lung cancer drug candidate failing to meet survival expectations.
Pfizer's stock declines 1.2% amid cautious analyst sentiment and CFO departure
Pfizer's stock experienced a 1.2% decline, closing at $24.75 on July 20, 2026. This downturn is attributed to cautious analyst sentiment, with several firms recently lowering price targets, and the announcement of CFO Dave Denton's departure, effective August 15. Despite reaffirming its 2026 revenue guidance of $59.5 billion to $62.5 billion, the stock's consensus rating remains 'Hold' with an average target price of $28.50.
Pfizer's stock remains below key moving averages amid ongoing challenges.
Pfizer's stock continues to trade below its 50-day and 200-day simple moving averages, reflecting investor caution regarding the company's growth prospects. The stock closed at $25.05 on July 17, 2026, with an intraday high of $25.64 and a low of $24.975. Analysts have expressed concerns over declining COVID-related revenues and patent expirations, which may impact future earnings. Additionally, HSBC downgraded Pfizer's rating to 'Hold' due to a lack of near-term catalysts.
Analyze any chart in seconds
This is today's read on Pfizer. Point your camera at any chart and ChartDetector AI gives you a full technical analysis in seconds — free on iOS.
AI-generated from public news sources. Not financial advice.